• 1. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 2. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 3. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 4. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 5. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrazinium compounds

Recent Advances in the Study of 2,5-Dimethyl Pyrazine N-Oxide (CAS: 6890-37-5) in Chemical Biology and Pharmaceutical Research

2,5-Dimethyl pyrazine N-oxide (CAS: 6890-37-5) is a heterocyclic compound that has garnered significant attention in recent years due to its potential applications in chemical biology and pharmaceutical research. This compound, characterized by its unique pyrazine N-oxide structure, has been explored for its diverse biological activities, including antimicrobial, anti-inflammatory, and anticancer properties. Recent studies have focused on elucidating its mechanism of action, optimizing its synthesis, and evaluating its therapeutic potential in various disease models.

A study published in the Journal of Medicinal Chemistry (2023) investigated the antimicrobial activity of 2,5-dimethyl pyrazine N-oxide against multidrug-resistant bacterial strains. The researchers found that the compound exhibited potent inhibitory effects against Staphylococcus aureus and Escherichia coli, with minimum inhibitory concentrations (MICs) comparable to those of standard antibiotics. The study also proposed a mechanism involving disruption of bacterial cell membrane integrity, supported by electron microscopy and molecular dynamics simulations. These findings highlight the potential of 2,5-dimethyl pyrazine N-oxide as a lead compound for developing novel antimicrobial agents.

In the realm of anticancer research, a recent preprint on bioRxiv (2024) explored the compound's ability to induce apoptosis in cancer cells. The study demonstrated that 2,5-dimethyl pyrazine N-oxide selectively targeted cancer cells by activating the intrinsic apoptotic pathway, as evidenced by increased caspase-3 activity and mitochondrial membrane depolarization. Notably, the compound showed minimal cytotoxicity against normal human fibroblasts, suggesting a favorable therapeutic window. Further proteomic analysis revealed that the compound modulated key signaling pathways involved in cell proliferation and survival, providing a molecular basis for its anticancer effects.

From a chemical synthesis perspective, a breakthrough in the scalable production of 2,5-dimethyl pyrazine N-oxide was reported in Organic Process Research & Development (2023). The research team developed a novel catalytic oxidation method using environmentally benign oxidants, achieving a yield of over 85% with high purity. This advancement addresses previous challenges in the large-scale synthesis of the compound, paving the way for its broader application in drug discovery and development. The optimized synthetic route also demonstrated excellent reproducibility and cost-effectiveness, making it attractive for industrial-scale production.

Ongoing clinical investigations are exploring the pharmacokinetic profile and safety of 2,5-dimethyl pyrazine N-oxide derivatives. Preliminary results from Phase I trials indicate good oral bioavailability and a half-life suitable for once-daily dosing. Researchers are particularly interested in its potential as a dual-action agent, combining antimicrobial and anti-inflammatory properties, which could be beneficial for treating complex infections associated with chronic inflammation. However, further studies are needed to fully characterize its metabolism and potential drug-drug interactions.

In conclusion, recent research on 2,5-dimethyl pyrazine N-oxide (CAS: 6890-37-5) has significantly advanced our understanding of its biological activities and therapeutic potential. The compound's unique chemical structure and diverse pharmacological effects make it a promising candidate for multiple therapeutic areas. Future research directions include structure-activity relationship studies to optimize its potency and selectivity, as well as investigations into its potential synergistic effects with existing drugs. As the scientific community continues to explore this interesting molecule, it may offer new opportunities for addressing unmet medical needs in infectious diseases and oncology.

• 6890-38-6(Pyrazine, 2,5-dimethyl-, 1,4-dioxide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)